Enovis CAO Oliver Engert buys $149,970 in company stock
What it means
- What to watch: There is a hard number in this story ($149,970) — the interesting part is how it compares with the last few like it.
- How the stock is trading: $ENOV +8.52% in the latest session.
- Timing: It arrived overnight — the change beside it belongs to a session that had already packed up and gone home. Market holidays are not detected.
Where the stock stands
$ENOV last changed hands at $26.50, +8.52% on the session, 18% below its 52-week high of $32.41 and 59% above its low of $16.70 — a little above the middle of the range. Over the year it has ranged 94% from low to high: a wide band, so a several-percent week is just a week. These are latest-session quotes, not live prices — the live tape is on the $ENOV page.
How much coverage it is getting
Nothing else on $ENOV in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner has Health Care reading calm today: no unusual stress in the filings and disclosures it watches.
Coming up
$ENOV earnings today. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
For the receipts, the $ENOV page has the full chart, the filings and the valuation model these figures come from. Comparing how two or three outlets frame the same story is the fastest way to separate the facts from the angle. Wook AI, above, can pull live figures and run the numbers on request — how far $ENOV is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $ENOV. It carried $149,970, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on September 5, 2026. $ENOV has moved +32.63% ($19.98 to $26.50). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.